EDIT - CIK 0001650664
The table below shows Editas Medicine, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$165.24M | -$210.28M | -$132.18M | -$177.35M | -$163.80M | -$179.84M |
| Capital expenditure | $607.00K | $8.83M | $4.72M | $4.12M | $7.98M | $7.16M |
| Investing cash flow | $138.67M | $162.15M | -$3.73M | $114.07M | -$54.47M | -$140.52M |
| Dividends paid | - | - | - | - | - |
Editas Medicine, Inc. reported operating cash flow of -$165.24M for fiscal year 2025. That is up 21.4% from -$210.28M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$50.25M (FY 2016) to -$165.24M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $40.47M | $56.03M | $118.04M | $1.28M | $282.11M | $224.12M |